$CTNM News

Morgan Stanley Maintains Equal-Weight on Contineum Therapeutics, Raises Price Target to $16

Contineum Therapeutics Q1 EPS $(0.39) Beats $(0.51) Estimate

Contineum Therapeutics Stock Edges Higher As PIPE-791 Pain Data Clears Safety Bar

Contineum Therapeutics Announces Its Phase 1b Study Of PIPE-791 Meets Primary Endpoint By Demonstrating At Least 30% Reduction In Chronic Pain

Baird Maintains Outperform on Contineum Therapeutics, Raises Price Target to $20

Contineum Therapeutics (NASDAQ:CTNM) Reports Q4 2025 Loss, Highlights Clinical Progress and Extended Cash Runway

Contineum Therapeutics Q4 Earnings Summary & Key Takeaways

Contineum Therapeutics Q4 EPS $(0.49) Beats $(0.59) Estimate

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics, Inc. (NASDAQ:CTNM) surges 10%; retail investors who own 51% shares profited along with institutions

Contineum Therapeutics shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight rating and lowered its price target from $23 to $14.

Contineum Therapeutics shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight rating and lowered its price target from $23 to $14.

Morgan Stanley Downgrades Contineum Therapeutics to Equal-Weight, Lowers Price Target to $14

Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?

Contineum Therapeutics shares are trading lower after the company announced the pricing of its $90 million million public offering of 7,346,938 shares at $12.25 per share.

Reported Earlier, Contineum Therapeutics Prices Upsized $90.0M Public Offering Of 7,346,938 Class A Common Shares At $12.25 Per Share

Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering

Contineum Therapeutics Announces Proposed $75.0 Million Public Offering

Contineum Therapeutics shares are trading lower after the company announced a proposed $75 million public offering of Class A common shares.